For the quarter ending 2025-09-30, PLX had -$4,248K decrease in cash & cash equivalents over the period. -$4,230K in free cash flow.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | 2,355 | -3,455 |
| Share-based compensation | 598 | 967 |
| Depreciation | 372 | 706 |
| Financial expenses, net | -28 | -108 |
| Changes in accrued liability for employee rights upon retirement | 4 | 10 |
| Changes in deferred income tax asset | 59 | 118 |
| Gain on amounts funded in respect of employee rights upon retirement | 12 | 6 |
| Decrease (increase) in accounts receivable-trade and other assets | 4,849 | 6,919 |
| Changes in operating lease right of use assets, net | 24 | 38 |
| Decrease (increase) in inventories | 124 | -112 |
| Decrease in accounts payable and accruals | -2,139 | -1,894 |
| Net cash provided by (used in) operating activities | -3,732 | -10,291 |
| Purchase of property and equipment | 498 | 737 |
| Amounts funded in respect of employee rights upon retirement, net | 6 | 13 |
| Net cash provided by (used in) investing activities | -504 | -750 |
| Proceeds from issuance of common stock under the sales agreement, net | 0 | 6,812 |
| Exercise of warrants and options | 0 | 2,368 |
| Net cash provided by (used in) financing activities | 0 | 9,180 |
| Effect of exchange rate changes on cash and cash equivalents | -12 | -4 |
| Net increase (decrease) in cash and cash equivalents | -4,248 | -1,865 |
| Cash and cash equivalents at beginning of period | 19,760 | - |
| Cash and cash equivalents at end of period | 13,647 | - |
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)